<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682055</url>
  </required_header>
  <id_info>
    <org_study_id>VK-2019-001</org_study_id>
    <nct_id>NCT03682055</nct_id>
  </id_info>
  <brief_title>Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cullinan Oncology, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cullinan Oncology, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with&#xD;
      EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and&#xD;
      Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a, open-label, multicenter, first-in-human trial to evaluate the safety&#xD;
      and tolerability, PK, PD, and preliminary efficacy of VK-2019 in patients with EBV-positive&#xD;
      NPC.&#xD;
&#xD;
      This trial is divided into three parts: Phase 1 Dose Escalation, Phase 1 Dose Expansion, and&#xD;
      Phase 2s Dose Expansion.&#xD;
&#xD;
      The objectives of the dose escalation part are to determine the safety, tolerability, MTD,&#xD;
      recommended Phase 2 dose (RP2D), and to evaluate the anti-tumor activity of orally&#xD;
      administered VK-2019 monotherapy. Additional objectives are to determine the pharmacokinetic&#xD;
      (PK) profile of VK-2019.&#xD;
&#xD;
      VK-2019 will be dosed once daily (QD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">August 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 23, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cohorts: The frequency, severity, and duration of AEs and DLTs, AEs leading to discontinuation, and AEs leading to death.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: The durable overall response rate (ORR).</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: ORR</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Duration of response (DOR)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Six month disease control rate (DCR-6)</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Twelve month disease control rate (DCR-12)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Rate of survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Incidence of safety laboratory assessment abnormalities</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Incidence of abnormalities in vital signs or other clinical safety assessments.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: ORR</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: DOR</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Dose Expansion Cohorts: DCR</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Rate of partial or complete plasma EBV DNA antiviral response during treatment (assessed as 3xlog10 reduction or a drop below the lower limit of detection of the assay [LLOD], respectively).</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Maximum measured concentration in serum (Cmax)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Minimum measured concentration in serum (Cmin)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Time from dosing to maximum measured concentration (tmax)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Area under the serum concentration-time curve (AUC)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Terminal half-life (t1/2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Phase 2a Dose Expansion Cohorts: Exploratory PD assay for EBER in situ hybridization levels in baseline and on treatment tumor biopsies in a limited number of patients at MTD.</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation (Accelerated Titration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation (Rolling Six)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion(s)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a Dose Expansion(s)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VK-2019</intervention_name>
    <description>EBNA1 inhibitor</description>
    <arm_group_label>Phase 1 Dose Escalation (Accelerated Titration)</arm_group_label>
    <arm_group_label>Phase 1 Dose Escalation (Rolling Six)</arm_group_label>
    <arm_group_label>Phase 1 Dose Expansion(s)</arm_group_label>
    <arm_group_label>Phase 2a Dose Expansion(s)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained prior to any protocol mandated assessment.&#xD;
&#xD;
          2. Age ≥ 18.&#xD;
&#xD;
          3. Either loco regionally recurrent or metastatic EBV positive nasopharyngeal carcinoma&#xD;
             not amenable to curative treatment. EBV positivity is defined as high EBV viral load&#xD;
             in plasma (&gt; 4000 genomes per µg plasma DNA) and/or biopsy tissue positive for EBV.&#xD;
&#xD;
          4. Prior palliative radiation must have been completed at least 2 weeks prior to study&#xD;
             Cycle 1 Day 0.&#xD;
&#xD;
          5. Prior anti cancer systemic treatment must have been completed greater than 4 weeks&#xD;
             prior to study Cycle 1 Day 0.&#xD;
&#xD;
          6. Toxicities related to prior anti-cancer therapy must have returned to Grade 1 or less.&#xD;
             Peripheral neuropathy must be Grade 2 or less. Chronic but stable toxicities Grade &gt; 1&#xD;
             (e.g., dysphasia, G tube dependence, etc.) may be allowed after agreement between the&#xD;
             Investigator and Sponsor.&#xD;
&#xD;
          7. For the dose expansion phase only: Patients must have RECIST v1.1 measurable disease,&#xD;
             defined as at least one lesion that can be accurately measured in at least one&#xD;
             dimension (longest diameter to be recorded for non nodal lesions and short axis for&#xD;
             nodal lesions) as ≥ 10 mM with spiral CT scan, MRI, or calipers by clinical exam.&#xD;
&#xD;
          8. ECOG performance status score of ≤ 2 at study entry.&#xD;
&#xD;
          9. Absolute neutrophil count &gt; 1500/µL (stable off any growth factor within 1 week of&#xD;
             study drug administration).&#xD;
&#xD;
         10. Hemoglobin &gt; 9g/dL (transfusion to achieve this level is permitted).&#xD;
&#xD;
         11. Platelet count &gt; 75 x 103/ µL (transfusion to achieve this level is NOT permitted).&#xD;
&#xD;
         12. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper&#xD;
             limit of normal (ULN).&#xD;
&#xD;
         13. Total serum bilirubin ≤ 1.5 x ULN.&#xD;
&#xD;
         14. Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min as calculated per&#xD;
             Cockcroft Gault equation.&#xD;
&#xD;
         15. Urinary protein &lt; 2+ by dipstick. If dipstick ≥ 2+, then a 24 hour urine collection&#xD;
             can be done and the patient may enter only if urinary protein is &lt; 1 g/24 hour.&#xD;
&#xD;
         16. Sexually active patients must agree to utilize birth control method during the study&#xD;
             and for 18 weeks after the study is concluded, using effective birth control methods&#xD;
             as defined in&#xD;
             https://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/contraceptive_methods_5&#xD;
             08.pdf.&#xD;
&#xD;
         17. Willingness and ability to comply with the study scheduled visits, treatment plans,&#xD;
             laboratory tests and other procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe or active symptomatic cardiopulmonary diseases (unstable angina and/or&#xD;
             congestive heart failure or peripheral vascular disease within the last 12 months;&#xD;
             chronic obstructive pulmonary disease exacerbation other respiratory illness requiring&#xD;
             hospitalization) or clinically significant psychiatric disorders; patients with&#xD;
             effectively treated conditions (eg, stenting for CAD) are eligible.&#xD;
&#xD;
          2. Metastatic disease with active central nervous system (CNS) involvement, defined as&#xD;
             parenchymal brain involvement. Patients with cranial nerve or base of skull&#xD;
             involvement without the above are eligible; Patients with CNS metastases stable 1&#xD;
             month following focal treatment with radiation are eligible.&#xD;
&#xD;
          3. Concurrent treatment with systemic cancer directed therapy including complementary,&#xD;
             alternative, herbal or nutritional supplement based treatments whose purpose is for&#xD;
             anti cancer effect.&#xD;
&#xD;
          4. Positive for human immunodeficiency virus (HIV) are not excluded from this study, but&#xD;
             HIV positive patients must have:&#xD;
&#xD;
               -  A stable regimen of highly active anti retroviral therapy (HAART)&#xD;
&#xD;
               -  No requirement for concurrent antibiotics or antifungal agents for the prevention&#xD;
                  of opportunistic infections&#xD;
&#xD;
               -  A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard&#xD;
                  PCR based test&#xD;
&#xD;
          5. Serious uncontrolled medical disorder or active infection which would, in the opinion&#xD;
             of the Investigator, impair the ability of the subject to receive protocol therapy or&#xD;
             whose control may be jeopardized by the complications of this therapy.&#xD;
&#xD;
          6. Currently taking drugs that inhibit or induce OATP1B1 or OATP1B3 within 5 half lives&#xD;
             of that agent. Examples are included in Appendix 2.&#xD;
&#xD;
          7. Have received a prior organ allograft or allogeneic bone marrow transplant.&#xD;
&#xD;
          8. Current non prescription drug or alcohol dependence.&#xD;
&#xD;
          9. For all female patients, pregnancy or breastfeeding.&#xD;
&#xD;
         10. All female patients with reproductive potential must have a negative pregnancy test&#xD;
             (serum or urine) prior to enrollment.&#xD;
&#xD;
         11. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, or may interfere with the interpretation of study results, or in&#xD;
             the judgment of the investigator would make the patient inappropriate for entry into&#xD;
             the study.&#xD;
&#xD;
         12. Corrected QT by Fridericia's formula (QTcF) of &gt; 470 ms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Dimitrios Colevas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine, Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hong Kong University - Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Young LS. Epstein-Barr virus at 50-future perspectives. Chin J Cancer. 2014 Nov;33(11):527-8. doi: 10.5732/cjc.014.10208.</citation>
    <PMID>25367333</PMID>
  </reference>
  <reference>
    <citation>Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014 Dec;33(12):581-90. doi: 10.5732/cjc.014.10197. Epub 2014 Nov 21.</citation>
    <PMID>25418193</PMID>
  </reference>
  <reference>
    <citation>Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732). pii: 20160270. doi: 10.1098/rstb.2016.0270. Review.</citation>
    <PMID>28893937</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>NPC</keyword>
  <keyword>EBV</keyword>
  <keyword>EBNA1 inhibitor</keyword>
  <keyword>VK-2019</keyword>
  <keyword>Nasopharynx cancer</keyword>
  <keyword>Nasopharynx carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

